BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have submitted Phase 1 data to the FDA to support the evaluation of their COVID-19 booster dose for future licensure.  The data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.

Do You Need A COVID-19 Booster Dose? Pfizer-BioNTech Submit Initial Data To Support Idea

eBay

PayPal

In yesterday' Market360, I showed you an example of when it's a good idea to let a fundamentally superior stock like BioNTech SE (NASDAQ:BNTX) keep running. Source: Shutterstock Today, I'm going to show you the other side of the coin — how I know when it's time to cut loose a stock that had been.

When It's Time to “Cut and Run” on a Strong Stock

CureVac B.V

Novavax

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today appeared first on InvestorPlace.

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today

Moderna

Find out what's sending stocks in a high-growth area down so sharply.

These Nasdaq Vaccine Stocks Are Feeling the Pain Monday

Pfizer Inc. PFE, +0.33% and partner BioNTech SE BNTX, -10.29% announced Monday that data from a Phase 1 study has been submitted to the U.S. Food and Drug Administration, for the evaluation of a third, booster dose of their COVID-19 vaccine. The companies said they will also submit the data to the European Union's version of the FDA, the European Medicines Agency, as well as other regulatory authorities, in the coming weeks.

Pfizer, BioNTech submit trial data on COVID-19 booster shot to FDA

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies' COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “Vaccination is our most effective means of preve

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

The FDA authorized booster doses for immunocompromised individuals.

Why Pfizer, BioNTech, and Moderna Stocks Are Getting a Bump Today

BioNTech SE: From Speculative To Portfolio Must-Have (Part 1)

Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.

mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally

BioNTech, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently, marking an increase of about 5x. This compares to the S&P 500 which is up by just about 20% over the same period.

What Drove BioNTech Stock's Incredible Rise From $80 To $420 This Year?

mRNA vaccine technology could be the key to finally stopping a disease that kills hundreds of thousands of people every year. Malaria kills hundreds of thousands of people each year, mostly children under the age of five living in Africa.

After making the first COVID vaccine, BioNTech is taking on malaria

The EU's drug regulator is looking at reports about skin rash and kidney problems.

Moderna, BioNTech tumble 19% amid report the EU is looking into COVID vaccine side effects

BioNTech SE – ADR (NASDAQ:BNTX) shares are trading lower by 12.6% at $364 Wednesday morning after findings from a recent Mayo Clinic study showed competitor Moderna's COVID-19 vaccine could possibly be more effective against the Delta variant. Before the market open Wednesday, Bryan Garnier analyst Olga Smolentseva upgraded BioNTech Wednesday from Neutral to Buy and announced a $451 price target.

Why BioNTech's Stock Is Trading Lower Wednesday

United Continental Hlds

Workhorse Group

Dicerna Pharmaceuticals

Livent Corp

Southwest Airlines

Unity Software

Weightwatchers International Inc.

With the trading day almost halfway over, the S&P 500 and Dow Jones industrial average hit even more record highs in Wednesday's session.

Wednesday Afternoon Analyst Upgrades and Downgrades: BioNTech, United Airlines, Workhorse and More

Researchers might have found some difference between mRNA vaccine makers.

Why Shares of BioNTech Were Falling Today

The stock price of BioNTech SE (NASDAQ: BNTX) increased 14.97% today. This is why it happened.

BNTX Stock Price Increased 14.97%: Why It Happened

Coronavirus fears sparked a rally in the shares of the major vaccine makers.

Why Moderna, BioNTech, and Novavax Stock Soared Today

Shares of Moderna and BioNTech both skyrocketed on Monday amid growing enthusiasm over technology used in their coronavirus vaccines and its potential to help fight other ailments like cancer and malaria.

Moderna and BioNTech shares skyrocket amid talk of mRNA treatments for cancer, malaria

BioNTech SE (BNTX) CEO Ugur Sahin on Q2 2021 Results - Earnings Call Transcript

Vaccine demand is likely to persist well into next year, the company said, with more than a billion doses still left to be delivered in 2022 and beyond.

BioNTech rallies 16% after boosting the sales forecast for its COVID-19 vaccine and projecting sturdy demand ahead

Johnson & Johnson

There's major potential for all of these biotech stocks, especially after full FDA approval, but this one stands to be one of the top winners. The post Why These Biotech Stocks Are Soaring appeared first on InvestorPlace.

Why These Biotech Stocks Are Soaring

BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca, the German biotech group said on Monday.

BioNTech says has supplied more than 1 billion COVID-19 vaccine doses so far

BioNTech SE (NASDAQ: BNTX) reports Q2 FY21 revenues of €5.31 billion compared to €41.7 million a year ago, primarily due to an increase in the supply of COVID-19 vaccine worldwide. Revenues more than doubled from €2.04 billion sales in Q1 FY21.

BioNTech Records Stupendous Q2 Sales, Earnings Growth; Estimates FY21 COVID-19 Vaccine Revenues Of €15B

Shares of BioNTech (NASDAQ:BNTX) rose 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 3188.10% over the past year to $12.97, which beat the estimate of $8.91.

Recap: BioNTech Q2 Earnings

Conference call and webcast scheduled for August 9, 2021, at 8:00 a.m. ET (2:00 p.m. CET)

News for BioNTech SE Stock (BNTX)